TITLE

Cancer Not for the Dogs

PUB. DATE
July 2009
SOURCE
Pharmaceutical Representative;Jul2009, Vol. 39 Issue 7, p11
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the U.S. Food and Drug Administration's (FDA's) approval of Palladia (toceranib phosphate) to treat cancer in dogs. It notes that the drug treats canine cutaneous mast cell tumors. It treats tumors with or without the involvement of regional lymph node. It is also considered as a significant step for veterinary medicine.
ACCESSION #
42732615

 

Related Articles

  • New approvals.  // Pharmacy Today;Jan2013, Vol. 19 Issue 1, p19 

    The article reports on the approval by the U.S. Food and Drug Administration (FDA) of the cancer drug amatuximab from Morphotek and the multiple-receptor tyrosine kinase inhibitor cabozantinib from Exelixis.

  • Imbruvica approval marks 'new era' for CLL treatment. Todak, Alexandra; Leiser, Mark // Hem/Onc Today;3/10/2014, Vol. 15 Issue 5, p1 

    The article discusses the decision of the U.S. Food and Drug Administration (FDA) in March 2014 to approve Bruton's tyrosine kinase inhibitor ibrutinib for patients with previously treated chronic lymphocytic leukemia.

  • Nintedanib: First Global Approval. McCormack, Paul // Drugs;Jan2015, Vol. 75 Issue 1, p129 

    Nintedanib (Ofev) is an orally available, small, multiple receptor tyrosine kinase inhibitor developed by Boehringer Ingelheim for the treatment of idiopathic pulmonary fibrosis (IPF) and cancer. Nintedanib received its first global approval in the US in October 2014 for the treatment of IPF....

  • FDA Splits with Panel; Approves Tarceva in NSCLC Maintenance. Boggs, Jennifer // BioWorld Today;4/20/2010, Vol. 21 Issue 75, p1 

    This article deals with the approval given by the U.S. Food and Drug Administration (FDA) to Tarceva or erlotinib as a maintenance therapy for non-small-cell lung cancer (NSCLC) patients. It notes that the FDA decision would provide a modest boost to sales of the drug from OSI Pharmaceuticals...

  • FDA Surprises Ariad with Early Nod for Ponatinib in CML, ALL. Boggs, Jennifer // BioWorld Today;12/17/2012, Vol. 23 Issue 243, p1 

    The article reports on the approval received by Ariad Pharmaceuticals Inc. from the U.S. Food and Drug Administration (FDA) for its BCR-ABL inhibitor ponatinib. According to Ariad Chief Executive Officer (CEO) Harvey Berger, the firm's commercial team is fully trained and ready to launch in...

  • Et Tu, Ibrutinib? Pharmacyclics NDA in Lymphomas Accepted. Osborne, Randy // BioWorld Today;8/30/2013, Vol. 24 Issue 167, p1 

    The article reports on the payment received by Pharmacyclics Inc. from Janssen Biotech Inc, a unit of Johnson & Johnson (J&J), for the progress with the oral Burton's tyrosine kinase inhibitor ibrutinib. The U.S. Food and Drug Administration (FDA) approved the drug application (NDA) of...

  • Imbruvica Gets an FDA Nod In Mantle Cell Lymphoma. Powers, Marie // BioWorld Today;11/14/2013, Vol. 24 Issue 220, p1 

    The article reports on the approval given by the U.S. Food and Drug Administration (FDA) to Imbruvica (ibrutinib), the oral Bruton's tyrosine kinase (BTK) inhibitor for treatment of patients with mantle cell lymphoma (MCL), developed by Pharmacyclics Inc. and Johnson & Johnson unit Janssen...

  • Nilotinib: A tyrosine kinase inhibitor for CML. Tanzi, Maria G. // Pharmacy Today;Jan2008, Vol. 14 Issue 1, p22 

    The article reports on the approval of the Nilotinib drug, a tyrosine kinase inhibitor, manufactured by Novartis AG in the U.S. This drug was approved by the Food and Drug Administration for the treatment of chronic and accelerated-phase Philadelphia chromosome-positive chronic myelogenous...

  • The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib. Masiello, David; Gorospe, Gerry; Yang, Allen S. // Journal of Hematology & Oncology;2009, Vol. 2, p1 

    Tyrosine kinase inhibitors (TKIs) like dasatinib and nilotinib are indicated as second-line treatment for chronic myeloid leukemia resistant or intolerant to the current first-line TKI imatinib. These are agents are well tolerated, but potent and as such should be monitored for potentially...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics